Skip to main content

Brain Ischemia,Stoke

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Dyslipidemia Management in Chinese Post Stroke PatientsN/A1 trial
Active Trials
NCT01897883Completed5,000Est. Aug 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AstraZenecaDyslipidemia Management in Chinese Post Stroke Patients

Clinical Trials (1)

Total enrollment: 5,000 patients across 1 trials

NCT01897883AstraZenecaDyslipidemia Management in Chinese Post Stroke Patients

Dyslipidemia Management in Chinese Post Stroke Patients

Start: Jul 2013Est. completion: Aug 20145,000 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.